The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Lars Wallentin

Uppsala Clinical Research Centre

Uppsala University




Name/email consistency: high



  • Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden. 2003 - 2010
  • Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden. 2008


  1. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin, L., James, S., Storey, R.F., Armstrong, M., Barratt, B.J., Horrow, J., Husted, S., Katus, H., Steg, P.G., Shah, S.H., Becker, R.C. Lancet (2010) [Pubmed]
  2. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Wallentin, L., Yusuf, S., Ezekowitz, M.D., Alings, M., Flather, M., Franzosi, M.G., Pais, P., Dans, A., Eikelboom, J., Oldgren, J., Pogue, J., Reilly, P.A., Yang, S., Connolly, S.J. Lancet (2010) [Pubmed]
  3. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K.W., Scirica, B.M., Skene, A., Steg, P.G., Storey, R.F., Harrington, R.A., Freij, A., Thorsén, M. N. Engl. J. Med. (2009) [Pubmed]
  4. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Wallentin, L. Eur. Heart J. (2009) [Pubmed]
  5. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Wallentin, L., Varenhorst, C., James, S., Erlinge, D., Braun, O.O., Jakubowski, J.A., Sugidachi, A., Winters, K.J., Siegbahn, A. Eur. Heart J. (2008) [Pubmed]
  6. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Wallentin, L., Goldstein, P., Armstrong, P.W., Granger, C.B., Adgey, A.A., Arntz, H.R., Bogaerts, K., Danays, T., Lindahl, B., Mäkijärvi, M., Verheugt, F., Van de Werf, F. Circulation (2003) [Pubmed]
  7. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Wallentin, L., Wilcox, R.G., Weaver, W.D., Emanuelsson, H., Goodvin, A., Nyström, P., Bylock, A. Lancet (2003) [Pubmed]
WikiGenes - Universities